Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers

ConclusionsOur study shows that long IO-free periods can be achieved with limited duration of anti-PD-(L)1 therapy with excellent survival outcomes, and that anti-PD-(L)1 re-challenge is feasible in clinical practice.

Source: Journal of Cancer Research and Clinical Oncology - June 30, 2020 Category: Cancer & Oncology Source Type: research